Celcuity’s Phase 3 VIKTORIA-1 Results Highlight Promising New Pathway for Advanced Breast Cancer Patients with PIK3CA Mutations
Significant Clinical Progress in Targeting the PAM Pathway for Breast Cancer
Celcuity Inc. (NASDAQ:CELC) announced a substantial milestone today, reporting that its Phase 3 VIKTORIA-1 clinical trial achieved its primary endpoint for patients with hormone receptor positive, HER2-negative (HR+/HER2-) advanced breast cancer harboring PIK3CA mutations. The positive topline results signal a meaningful advancement in progression-free survival for a patient group that traditionally faces limited treatment options after initial therapy resistance.
Gedatolisib Outperforms Standard of Care in Trial
The VIKTORIA-1 study compared gedatolisib-based regimens to the standard alpelisib and fulvestrant therapy. Results demonstrated that patients receiving the "gedatolisib triplet" (gedatolisib plus fulvestrant and palbociclib) experienced both statistically significant and clinically meaningful improvements in progression-free survival. Notably, the "gedatolisib doublet" (gedatolisib plus fulvestrant) also outperformed standard therapy in a secondary analysis. Both regimens showed manageable safety profiles, with no unexpected safety issues.
| Trial Arm | Included Therapies | Outcome vs. Standard | Safety |
|---|---|---|---|
| Gedatolisib Triplet | Gedatolisib + Fulvestrant + Palbociclib | Statistically significant and clinically meaningful PFS improvement | Well tolerated |
| Gedatolisib Doublet | Gedatolisib + Fulvestrant | PFS improvement (secondary endpoint) | Well tolerated |
| Standard of Care | Alpelisib + Fulvestrant | Baseline for comparison | Typical safety profile |
Broader Implications for HR+/HER2- Breast Cancer Treatment
The results offer hope for the approximately 40% of HR+/HER2- breast cancer patients whose tumors carry a PIK3CA mutation—a group that has historically seen limited benefits from therapies targeting only a single component of the PI3K/AKT/mTOR (PAM) pathway. Gedatolisib’s multi-target strategy interrupts multiple pathway components at once, which may help prevent tumors from developing resistance, a challenge seen with existing targeted inhibitors.
More than two million people are diagnosed with breast cancer each year globally, and 70% of cases are HR+/HER2- subtype. Among these, about four in ten patients present PIK3CA mutations, making today’s findings relevant for a substantial segment of patients facing advanced disease.
Regulatory Path Forward: FDA Review and ASCO Presentation
Celcuity intends to submit the new data to the FDA as a supplemental New Drug Application (sNDA), with the company aiming to broaden the potential patient base for gedatolisib. Additionally, these findings are scheduled for presentation as a late-breaking oral abstract at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2026. This high-profile venue could boost further clinical interest and regulatory momentum.
The FDA has already granted Priority Review to gedatolisib for patients with wild-type PIK3CA status, with a Prescription Drug User Fee Act (PDUFA) decision expected by July 17, 2026. The company’s strategy suggests future exploration into additional cancers involving the PAM pathway is underway.
Stocks React While Clinical Outlook Strengthens
As of 10:30 AM, Celcuity shares were trading at $146.96. While investors are clearly reacting to the therapeutics breakthrough and the prospect for gedatolisib to alter the standard of care, the true inflection point will depend on forthcoming full data disclosures and potential FDA approval.
Key Takeaway: Potential Paradigm Shift for PIK3CA-Mutant Breast Cancer
The VIKTORIA-1 results point to a noteworthy advance in treating advanced HR+/HER2- breast cancer with PIK3CA mutations. While comprehensive data will be critical for clinicians and regulators, Celcuity’s approach to targeting the full PI3K/AKT/mTOR pathway may set a new standard for patients who previously faced limited second-line options. The coming ASCO presentation and clinical details could offer further clarity on risk/benefit profiles and shape future treatment paradigms across multiple cancer segments.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI